Obsidian Therapeutics, a biotech company developing engineered cell and gene therapies for solid tumors, is rated Hold because its current market price appears overvalued. Its lead drug, OBX-115, shows promising early results in advanced melanoma but is still in early Phase 1/2 trials. With a market cap of $1.1 billion, the stock trades around $17 per share, while a risk-adjusted fair value estimate is about $10.16 per share. The company has cash to fund operations until mid-2028 but may face dilution, and significant upside depends on broader success of its cytoDRiVE platform across multiple diseases.
Ether's price surged 7.46% to $2619 following US inflation data showing 3.4% annual growth, in line with expectations. This triggered a relief rally as investors reacted positively to the absence of worse inflation news, with short sellers buying bac...
Revolut disclosed personal and financial data of some customers, including Bitcoin transaction histories, following a request that appeared to be from a legitimate government agency but was sent from an unauthorized email account. The exposed informa...
Fetch.ai has introduced the A2A Outbound Adapter, enabling its autonomous AI agents to communicate easily with external agents using the Google-linked A2A Protocol. This tool supports single or multiple server connections and includes features like a...
Titan Minerals reported new drilling results at its Dynasty Gold Project in Ecuador, including a 16-meter intercept at 2.8 g/t gold and 9.1 g/t silver extending mineralisation beyond the current resource. The company is expanding its drilling program...
Alkane Resources reported resource growth at its three producing mines—Björkdal, Tomingley, and Costerfield—during the 2026 financial year by replacing depletion through exploration. The updated inventory includes 8.64 million ounces of gold in measu...
